| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
17.71(B) |
| Last
Volume: |
477,045 |
Avg
Vol: |
726,924 |
| 52
Week Range: |
$143.71 - $212.05 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 824 |
| Guru Rank Value : 0.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
46,855 |
76,855 |
102,504 |
247,093 |
| Total Sell Value |
$7,107,715 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
| Total People Sold |
6 |
7 |
8 |
9 |
| Total Sell Transactions |
11 |
12 |
18 |
35 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2023-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,294 |
8,639 |
|
- |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2023-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
16,952 |
37,947 |
|
- |
|
| Franchini Indrani Lall |
EVP, CLO & Secretary |
• – – |
2023-04-06 |
4 |
AS |
$210.00 |
$735,000 |
D/D |
(3,500) |
0 |
|
-14% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2023-03-03 |
4 |
AS |
$200.00 |
$3,614,400 |
D/D |
(18,072) |
4,345 |
|
1% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2023-03-03 |
4 |
OE |
$96.45 |
$482,250 |
D/D |
5,000 |
22,417 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2023-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
136 |
136 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2023-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
136 |
136 |
|
- |
|
| Ausiello Dennis A |
Director |
– • – |
2023-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
136 |
136 |
|
- |
|
| Hamburg Margaret A |
Director |
– • – |
2023-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
136 |
136 |
|
- |
|
| Schulman Amy W |
Director |
– • – |
2023-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
136 |
136 |
|
- |
|
| Vaishnaw Akshay |
President |
• – – |
2023-02-10 |
4 |
AS |
$213.13 |
$8,216,324 |
D/D |
(38,044) |
14,970 |
|
-8% |
|
| Vaishnaw Akshay |
President |
• – – |
2023-02-10 |
4 |
OE |
$63.00 |
$1,947,519 |
D/D |
30,913 |
53,014 |
|
- |
|
| Tanguler Tolga |
EVP, Chief Commercial Officer |
• – – |
2023-02-03 |
4 |
AS |
$227.68 |
$794,854 |
D/D |
(3,424) |
0 |
|
-15% |
|
| Franchini Indrani Lall |
EVP, CLO & Secretary |
• – – |
2023-02-02 |
4 |
S |
$223.97 |
$378,563 |
D/D |
(1,675) |
3,500 |
|
14% |
|
| Tanguler Tolga |
EVP, Chief Commercial Officer |
• – – |
2023-02-02 |
4 |
AS |
$223.97 |
$361,839 |
D/D |
(1,601) |
3,424 |
|
-14% |
|
| Franchini Indrani Lall |
EVP, CLO & Secretary |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,175 |
5,175 |
|
- |
|
| Tanguler Tolga |
EVP, Chief Commercial Officer |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,025 |
5,025 |
|
- |
|
| Vaishnaw Akshay |
President |
• – – |
2022-12-05 |
4 |
D |
$226.20 |
$299,489 |
D/D |
(1,324) |
22,101 |
|
- |
|
| Vaishnaw Akshay |
President |
• – – |
2022-12-05 |
4 |
OE |
$42.22 |
$299,938 |
D/D |
5,079 |
23,425 |
|
- |
|
| Ausiello Dennis A |
Director |
– • – |
2022-11-21 |
4 |
AS |
$220.00 |
$4,950,000 |
D/D |
(22,500) |
0 |
|
-2% |
|
| Ausiello Dennis A |
Director |
– • – |
2022-11-21 |
4 |
OE |
$70.20 |
$1,599,638 |
D/D |
22,500 |
22,500 |
|
- |
|
| Sigal Charles Elliott |
Director |
– • – |
2022-08-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,000 |
|
7% |
|
| Sharp Philip A |
Director |
– • – |
2022-08-15 |
4 |
AS |
$226.16 |
$7,760,736 |
D/D |
(33,670) |
0 |
|
1% |
|
| Sharp Philip A |
Director |
– • – |
2022-08-15 |
4 |
OE |
$30.09 |
$1,137,066 |
D/D |
33,670 |
33,670 |
|
- |
|
| Tanguler Tolga |
EVP, Chief Commercial Officer |
• – – |
2022-08-05 |
4 |
AS |
$215.03 |
$401,630 |
D/D |
(1,841) |
0 |
|
8% |
|
475 Records found
|
|
Page 3 of 19 |
|
|
3.41 (2.31%) 
